Analysts Offer Insights on Healthcare Companies: Celgene (NASDAQ: CELG), Cidara Therapeutics (NASDAQ: CDTX) and Zimmer Biomet Holdings (NYSE: ZBH)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Celgene (NASDAQ: CELG), Cidara Therapeutics (NASDAQ: CDTX) and Zimmer Biomet Holdings (NYSE: ZBH).

Celgene (NASDAQ: CELG)

Leerink Swann analyst Geoff Porges maintained a Buy rating on Celgene (NASDAQ: CELG) on July 28 and set a price target of $160. The company’s shares closed on Friday at $134.10, close to its 52-week high of $139.

According to TipRanks.com, Porges is a 4-star analyst with an average return of 12.0% and a 59.2% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Theravance Biopharma.

Currently, the analyst consensus on Celgene is Strong Buy and the average price target is $152.15, representing a 13.5% upside.

In a report issued on July 26, Mizuho Securities also reiterated a Buy rating on the stock with a $134 price target.
Cidara Therapeutics (NASDAQ: CDTX)

Cidara Therapeutics (NASDAQ: CDTX) received a Sell rating from WBB Securities analyst Stephen Brozak on July 28. The company’s shares closed on Friday at $7.30.

According to TipRanks.com, Brozak is a 4-star analyst with an average return of 18.1% and a 50.0% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Cascadian Therapeutics, Cytosorbents Corp, and Seattle Genetics.

Cidara Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $13.75.

Zimmer Biomet Holdings (NYSE: ZBH)

In a report issued on July 28, Richard Newitter from Leerink Swann maintained a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH), with a price target of $146. The company’s shares closed on Friday at $123.78.

According to TipRanks.com, Newitter is a top 100 analyst with an average return of 24.9% and a 77.1% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Baxter International.

Currently, the analyst consensus on Zimmer Biomet Holdings is Moderate Buy and the average price target is $136.07, representing a 9.9% upside.

In a report issued on July 13, Argus Research also maintained a Buy rating on the stock with a $140 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.